Ionis Pharmaceuticals/IONS

$37.44

0.43%
-
1D1W1MYTD1YMAX

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).

Ticker

IONS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Brett Monia

Employees

927

Headquarters

Carlsbad, United States

IONS Metrics

BasicAdvanced
$5.4B
Market cap
-
P/E ratio
-$2.67
EPS
0.34
Beta
-
Dividend rate
$5.4B
0.34303
$54.44
$36.56
1.1M
7.373
7.28
415.133
430.099
-13.62%
-98.27%
-15.2%
7.007
18.337
18.352
34.84%
-15.47%
2.6%

What the Analysts think about IONS

Analyst Ratings

Majority rating from 24 analysts.
Buy

Price Targets

Average projection from 21 analysts.
50.08% upside
High $82.00
Low $29.00
$37.44
Current price
$56.19
Average price target

IONS Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-119.59% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$119M
-63.2%
Net income
-$143M
1,452.17%
Profit margin
-119.59%
4,125.8%

IONS Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 6.78%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.60
-$1.03
-$0.06
-$0.98
-
Expected
-$0.90
-$1.04
-$0.83
-$1.05
-$0.94
Surprise
-33.46%
-1.05%
-92.78%
-6.78%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Ionis Pharmaceuticals stock?

Ionis Pharmaceuticals (IONS) has a market cap of $5.4B as of May 28, 2024.

What is the P/E ratio for Ionis Pharmaceuticals stock?

The price to earnings (P/E) ratio for Ionis Pharmaceuticals (IONS) stock is 0 as of May 28, 2024.

Does Ionis Pharmaceuticals stock pay dividends?

No, Ionis Pharmaceuticals (IONS) stock does not pay dividends to its shareholders as of May 28, 2024.

When is the next Ionis Pharmaceuticals dividend payment date?

Ionis Pharmaceuticals (IONS) stock does not pay dividends to its shareholders.

What is the beta indicator for Ionis Pharmaceuticals?

Ionis Pharmaceuticals (IONS) has a beta rating of 0.34. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Ionis Pharmaceuticals stock price target?

The target price for Ionis Pharmaceuticals (IONS) stock is $56.19, which is 50.08% above the current price of $37.44. This is an average based on projections from 21 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Ionis Pharmaceuticals stock

Buy or sell Ionis Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing